I can't speak to specifics regarding history here in Canada or with Health Canada and the Purdue company.
I can say that there has been a dialogue, and it's ongoing, concerning abuse deterrence, abuse, as well as patient-safety-related outcomes. I myself have engaged in multiple discussions with folks who were concerned and interested in understanding the data we've been able to produce in the United States, and of course the determination FDA made in April of 2013 that the new formulation OxyNEO here in Canada has features that they find helpful from a public health perspective.
I'm encouraged, frankly, by Minister Ambrose's acknowledgement that she intends to re-examine the issue, again as one potential part of a multi-part solution.
If I may, I just want to add one other point.